

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CPD, LLC	06/10/2010

RECEIVING PARTY DATA

Name:	NeurEndo Pharma, LLC
Street Address:	5854 Schumann Drive
Internal Address:	Fitchburg Center
City:	Madison
State/Country:	WISCONSIN
Postal Code:	53711

PROPERTY NUMBERS Total: 9

Property Type	Number
Application Number:	11876279
Patent Number:	5727570
Patent Number:	6026817
Patent Number:	6262062
Patent Number:	6528520
Patent Number:	5878750
Patent Number:	6846831
Patent Number:	6919310
PCT Number:	US0782084

CORRESPONDENCE DATA

Fax Number: (608)258-7138
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 608-255-4440
 Email: ekenrick@whdlaw.com
 Correspondent Name: Whyte Hirschboeck Dudek, Grady Frenchick

CH \$360.00 11876279

501245995

**PATENT
 REEL: 024741 FRAME: 0902**

Address Line 1: 33 East Main Street
Address Line 2: Suite 300
Address Line 4: Madison, WISCONSIN 53703-4655

ATTORNEY DOCKET NUMBER:	NUR-14094
-------------------------	-----------

NAME OF SUBMITTER:	Grady J. Frenchick
--------------------	--------------------

Total Attachments: 3 source=NURassign#page1.tif source=NURassign#page2.tif source=NURassign#page3.tif

EXHIBIT A
ASSIGNMENT

WHEREAS, CPD, LLC, a Wisconsin limited liability company (hereinafter "ASSIGNOR") having its principal place of business at 5854 Schumann Drive, Fitchburg, Wisconsin 53711, is the owner of all patents and patent applications as set forth herein and on attached Schedule of Patents and Patent Applications ("Schedule") and to the invention(s) described therein;

AND WHEREAS, NeurEndo Pharma, LLC, a Wisconsin limited liability company (hereinafter "ASSIGNEE"), having its principal place of business at 5854 Schumann Drive, Fitchburg Center, Madison, WI 53711, is desirous of acquiring an interest therein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR by these presents does assign and transfer unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive rights to the aforesaid applications, to the inventions as described in the applications listed on the SCHEDULE, and including any and all provisional, non-provisional, continuations, continuations-in-part, divisionals, foreign counterparts, PCT, reexaminations, and reissues of the aforesaid patent application and patents that may issue thereon, in the United States and all foreign countries, together with the right of priority under the International Convention for the Protection of Industrial Property, Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States adheres, and hereby authorizes and requests the Commissioner of Patents to issue said patents to ASSIGNEE, for the sole use and benefit of ASSIGNEE, its successors, assigns and legal representatives,

AGREEING, FURTHERMORE, upon request of ASSIGNEE, and without further remuneration, to execute any and all papers desired by ASSIGNEE for the filing and granting of issued patents based on the invention(s) or improvement(s) therein, and the perfecting of title thereto in ASSIGNEE.

SCHEDULE OF PATENTS AND PATENT APPLICATIONS

Group I

All of the following lapsed U.S. patents as numbered and titled:

U.S. Patent 5,727,570

Method of Treating Hyperlipidemia in Humans

U.S. Patent 6,026,817

Method of Treating the Syndrome of Coronary Heart
Disease Risk Factors in Humans

U.S. Patent 6,262,062

Method of Treating the Syndrome of Coronary Heart
Disease Risk Factors in Humans

U.S. Patent 6,528,520

Method of Treating the Syndrome of Coronary Heart
Disease Risk Factors in Humans

Group II

All of the following issued and pending United States and international patent applications:

U.S. Patent 5,878,750

Method of Treating the Syndrome of Coronary Heart
Disease Risk Factors in Humans

U.S. Patent 6,846,831

Method of Treating the Syndrome of Lipodystrophy

U.S. Patent 6,919,310

Method of Treating the Syndrome of Coronary Heart
Disease Risk Factors in Humans

**U.S. Application No. 11/876,279, publication No.
2008108640**

Method of Restoring the Incretin Effect

International Application PCT/US2007/082084

Method of Restoring the Incretin Effect

EXECUTED as of the date(s) written below by ASSIGNOR:

ASSIGNOR:

CPD, LLC

Dated: 6/10/10

By: [Signature]

Name: [Signature]

Title: Chief Exec. Officer

STATE OF Wisconsin)
) SS


COUNTY OF Dane)

On this 10th day of June 2010, before me appeared Anton Clemens, the person who signed this instrument, who acknowledged that he or she signed it as a free act on behalf of the identified corporation.

[SEAL]

[Signature]
Notary Public

My Commission Expires: January 8, 2012



ASSIGNEE:

NeurEndo Pharma, LLC

Dated: 6/10/10

By: [Signature]

Name: Lance A. Ehrke

Title: Chairman

STATE OF Wisconsin)
) SS


COUNTY OF Dane)

On this 10th day of June 2010, before me appeared Lance Ehrke, the person who signed this instrument, who acknowledged that he or she signed it as a free act on behalf of the identified corporation.

[SEAL]

[Signature]
Notary Public

My Commission Expires:
January 8 2012



WHD/7148011.1